RPS6KB1 and acute myeloid leukemia: Everolimus combined with conventional 7+3 chemotherapy produced a complete remission (CR) rate of 68% in AML at first relapse that was correlated with the extent of plasma inhibition of phosphorylated p70S6K (P-p70S6K) [15].